Drug Safety Institute (DSI), a subsidiary of Brand Institute, was created in 2004. DSI is dedicated to improving the safe use of Pharmaceuticals by providing a global, state-of-the-art research model for proprietary (brand and line extension) and nonproprietary (USAN/INN) nomenclature research. In addition, DSI offers a medication error prevention analysis associated with labeling of pharmaceuticals, biological products and medical devices. DSI also offers various risk management strategies to our clients.
DSI’s methodology for proprietary name safety testing is in compliance with FDA, EMA, Health Canada, Japan’s Ministry of Health, Labour and Welfare and other regulatory agencies’ review guidelines.
Drug Safety Institute, a subsidiary of Brand Institute founded in 2004, provides the global pharmaceutical and biotech communities with regulatory expertise, strategy, and best practices in brand name and nonproprietary (USAN/INN) name development, name safety research, and comprehensive regulatory solutions.